| This week's sponsor is FierceBiotech. | | | |
Today's Rundown Pfizer drops iTeos IDO1 cancer drug due to lack of efficacy Roche aims for MacroGenics bull's-eye with $380M DART deal Arvinas in $830M-plus Pfizer biobucks deal BioNTech raises $270M A round to fuel mRNA, CAR-T R&D Enterome gets €32M, Bristol-Myers Squibb backing, for cancer work Antisense player Stoke Therapeutics picks up $40M series A Atlas-backed Generation Bio promises ‘druglike’ gene therapy Former FDA chief information officer and Takeda executive lands at Datavant Featured Story | | | Thursday, January 4, 2018 Pfizer has returned the rights to the IDO1 inhibitor it licensed from iTeos Therapeutics. The Big Pharma dumped the drug after failing to find signs of efficacy in a phase 1 brain cancer trial, but iTeos thinks it has a future and is preparing to raise money to power ahead solo. |
|
|
| This week's sponsor is Veeva. | | | [Webinar] Tufts eClinical Landscape Study: Q&A with Industry Experts
January 16, 2018 | 2pm ET / 11am PT
Hear expert analysis of the 2017 eClinical Landscape Survey, one of the largest, most in-depth surveys of clinical data management professionals that shows the impact of database build delays on trial timelines, as well as the projected increase of data source usage. Register Now |
Top Stories Thursday, January 4, 2018 After its $1.7 billion deal to buy out cancer biotech Ignyta in the dying days of 2017, Roche, ahead of J.P. Morgan’s annual meeting next week, has penned another deal, this time with DART player MacroGenics. Thursday, January 4, 2018 Yale spinout and previous Fierce 15 winner Arvinas, a biotech working on small molecule protein degradation therapies, has penned a deal potentially worth $830 million, and more besides, with Big Pharma Pfizer. Thursday, January 4, 2018 BioNTech has raised $270 million (€224 million). The series A round positions the German biotech to mount a multifront attack on cancer, spearheaded by mRNA therapies and supported by a clutch of other modalities including CAR-T cells. Thursday, January 4, 2018 French microbiome biotech Enterome has got off a €32 million ($38.5 million) series D round with the help of some big-name players. Thursday, January 4, 2018 Stoke's series A will support the development of its antisense approach to boost gene expression and treat disease caused by genetic insufficiency. Thursday, January 4, 2018 The gene therapy sector has a new player—Generation Bio—which promises to provide safer, more controllable treatments that do away with the need to use viruses for delivery. Thursday, January 4, 2018 Roivant Sciences’ clinical trial artificial intelligence arm Datavant has tapped bioinformatics expert Eric Perakslis, Ph.D., whose recent stint at Takeda will facilitate a new collaboration between the two firms, as its CSO. Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Sponsored by: Deloitte Sourcing research externally seems to be the preferred path for biopharma companies to strengthen their R&D pipeline. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Sponsored by: Veeva Systems Read Deloitte Consulting's whitepaper on the value of a holistic RIM capability, covering the potential cost savings and revenue gains from doing RIM right. Presented By: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: DSM Biomedical Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases. Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. FierceBiotech Executive Breakfast: Get Good Science and the Money will Follow January 9, 2018 | San Francisco, CA Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA Drug Approval, Manufacturing Quality & Regulation 2018 | Online Field Service Medical February 26-28, 2018 | Hilton La Jolla, Torrey Pines, CA | 